Affiliations: Lubin School of Business, Pace University, New York,
NY, USA
Abstract: The purpose of this paper is to discuss patent term extension
strategies for pharmaceutical companies in the United States. Market
exclusivity acquired through patents can yield higher prices and profits for
pharmaceutical products. Therefore, pharmaceutical companies use a variety of
strategies to increase market exclusivity of their products. Some of the
strategies discussed in this paper include one-year extension of time to file
for patent under the Paris convention, patent term restoration allowed by the
Waxman-Hatch Act, orphan drug exclusivity, pediatric exclusivity, the 30-month
stay provision and so on. Even though, the strategies discussed in this paper
are for the United States, they may be applicable to most European countries,
Australia, New Zealand, Japan, and Canada with minor modifications as similar
pharmaceutical regulations exist in these countries.
Keywords: patents, generics, pharmaceuticals, market exclusivity, Paris convention